Business Wire

NRF and Comexposium Expand Retail’s Big Show to Europe

Share

The National Retail Federation and Paris-based event organizer Comexposium today announced that the Paris Retail Week annual conference and exhibition is being rebranded beginning in 2025. The inaugural NRF 2025: Retail’s Big Show Europe will be held Sept. 16 – 18, 2025, at the Paris Porte de Versailles Pavilions 4 & 6. It is expected to draw thousands of retailers and business partners from across Europe.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240916040288/en/

“NRF is proud to represent the largest global retail brands in the world, and we are excited to expand our award-winning educational experiences into new markets, complementing the annual Big Show in New York City and Retail’s Big Show Asia Pacific,” NRF President and CEO Matthew Shay said. “Every single day, successful retailers are exploring new tools, new approaches and new innovations to remain relevant to loyal shoppers and new customers alike. For nearly 110 years, NRF has embraced the same culture of change in order to build and grow our first-in-class programming.”

NRF has participated in Paris Retail Week for several years, and this past June NRF and Comexposium jointly hosted the inaugural NRF Retail’s Big Show Asia Pacific. The sold-out inaugural event convened more than 6,000 business leaders and 300 technology providers for three days in Singapore. Now, the two organizations are broadening their partnership and bringing their collective expertise to one of the world’s greatest trendsetting and dynamic consumer-driven cities in the world.

“As one of the leading global event organizers, Comexposium built Paris Retail Week from the ground up. We are now committed, in partnership with NRF, to ensuring our combined experience will result in one of the most dynamic, sought after and highly attended retail events in Europe,” Comexposium Managing Director Laurent Noel said. “Paris Retail Week is a major event for European retailers. For more than 10 years, we have been bringing together more than 350 exhibitors each year, covering the entire value chain of omnichannel commerce. Paris Retail Week also features more than 200 conferences in plenary sessions and workshop rooms, covering all retail-related business issues. By joining forces with NRF, which shares our goal of helping retailers meet their business development challenges, we are bringing the best of both worlds to the market through a new event of unrivalled scope in Europe.”

The marriage of NRF Retail’s Big Show and Paris Retail Week to create Retail’s Big Show Europe will attract industry-leading speakers and premier content and innovations from across Europe. For more information, please visit nrfbigshoweurope.nrf.com.

About NRF
The National Retail Federation passionately advocates for the people, brands, policies and ideas that help retail succeed. From its headquarters in Washington, D.C., NRF empowers the industry that powers the economy. Retail is the nation’s largest private-sector employer, contributing $5.3 trillion to annual GDP and supporting more than one in four U.S. jobs — 55 million working Americans. For over a century, NRF has been a voice for every retailer and every retail job, educating, inspiring and communicating the powerful impact retail has on local communities and global economies. nrf.com

About Comexposium
The Comexposium Group is one of the leading event organizers worldwide, creating events that bring communities together to discover and explore businesses, passions and interests. Comexposium organizes more than 150 professional and general public events, connecting 48,000 exhibitors and 3.5 million visitors, 365 days a year. Comexposium is present in the retail sector with market-leading brands such as Paris Retail Week, Siec, One-to-one events in France and Monaco, Franchise shows in the US, and ad.Tech and iMedia in Asia-Pacific. www.comexposium.com

About Retail’s Big Show Europe
Retail’s most important event in Europe takes place in Paris from 16 – 18 September 2025. Be inspired by the biggest retail leaders across Europe in one of the world’s most dynamic and consumer-driven markets. Retail professionals from around the globe can experience three days of educational programming and an all-encompassing Expo featuring the latest retail solutions, as well as an Innovation Lab and Startup Zone featuring breakthrough technologies in Europe’s retail sector. nrfbigshoweurope.nrf.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20240916040288/en/

Contacts

Mary McGinty (855) NRF-PRESS
press@nrf.com

PERMALINK -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fnrf.com%2Fmedi
a-center%2Fpress-releases%2Fnrf-and-comexposium-expand-retails-big-show-europe&e
sheet=54122588&newsitemid=20240916040288&lan=en-US&anchor=PERMALINK&index=6&md5=
3f327b7f1e1ac0c3c64a9e46bdbaa04a

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and durable responses and offer the first BCL2 inhibitor for patients with R/R MCL, if approved,” said Lai Wang, PhD, Global Head of R&D, BeOne Medicines. “These data add to the remarkable progress we’ve seen over the past five years in treating B-cel

Oulu2026 – European Capital of Culture: Oulu to Unveil Full European Capital of Culture 2026 Programme – Live Stream on 4 September 202529.8.2025 11:46:00 EEST | Press release

Hundreds of partners are creating a year in which Northern Finland becomes a new hub of culture. The programme will offer something for everyone: large-scale exhibitions, festivals across all genres, world premieres, performing arts, village celebrations, permanent artworks, sports, and community events across a vast region of 40 municipalities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250829591577/en/ Oulu, with its 39 partner municipalities in Northern Finland, will step into the spotlight as European Capital of Culture 2026. The full programme will be officially launched on Thursday 4 September 2025 in Oulu, streamed live across Europe. The Oulu2026 programme is built around the theme of Cultural Climate Change, meaning a lasting enrichment of cultural life – connecting people through world-class experiences, creativity, and new ways of thinking. “2026 will be a transformative year – for our city, for Northern Finla

Nippon Sanso Holdings Group Unifies Global Brand Logo Launching the "NIPPON SANSO" Brand Worldwide29.8.2025 09:00:00 EEST | Press release

Nippon Sanso Holdings Corporation (President CEO: Toshihiko Hamada) will unify the brand logo for its industrial gas business globally and implement the change in stages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250828253560/en/ Until now, our group has operated industrial gas businesses worldwide using the same symbol mark, while adapting to each region. To further enhance recognition and understanding of our group as a unified entity among a broad range of stakeholders, and to maximize corporate value and achieve sustainable growth, we have decided to unify the brand for our industrial gas businesses as "NIPPON SANSO" and standardize the brand logo globally. Moving forward, we will continue striving to be a trusted company for all stakeholders as a globally recognized brand. *Please note that Thermos Group, which operates the consumer household goods business within our group, will not change its brand logo. *The log

TOM FORD Unveils Black Orchid Reserve Campaign Starring Tilda Swinton29.8.2025 07:35:00 EEST | Press release

The quest for exceptional rarity. Introducing Tilda Swinton for the new TOM FORD Black Orchid Reserve campaign. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250828507187/en/ “It is a profound honour for me to play a part in the history of TOM FORD’s legendary Black Orchid. Transformation, the blurring of boundaries and the celebration of magical properties have always drawn me close; Black Orchid Reserve is precisely such an enchantment.” — Tilda Swinton A celebrated actor and artist, Swinton is a singular presence known for her fearless artistry and transformative performances. An Academy Award, BAFTA and Golden Lion for Lifetime Achievement winner, Swinton defies conventions with elegance, intellect and a visionary approach to cinema. Her work transcends definition, shaping the culture through work in film, art and performance. TOM FORD creative director Haider Ackermann designed the campaign as a cinematic portrait of r

Novotech Supports Groundbreaking Approval of Anlotinib Combination Therapy for Advanced Soft Tissue Sarcoma28.8.2025 23:15:00 EEST | Press release

Novotech, a globally recognized full-service clinical research organization (CRO), is proud to have partnered with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ Pharma) in achieving a significant regulatory milestone: the approval of Anlotinib Hydrochloride Capsules for a new indication as a first-line treatment for unresectable locally advanced or metastatic soft tissue sarcoma (STS) in combination with chemotherapy. This approval marks the ninth indication for Anlotinib in China and represents the world’s first official approval of an Anlotinib-chemotherapy combination for first-line treatment of advanced or metastatic STS. Previously recommended as a second-line monotherapy by the Chinese Society of Clinical Oncology (CSCO) guidelines, Anlotinib was the only Grade I targeted therapy for STS. This new indication represents a significant advancement for patients who have not previously received systemic treatment, expanding access to more effective and targeted first-line the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye